Associate Vice President
Sanofi
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Christopher B Nelson, PhD MPH, Medical Evidence Generation Lead, North America, Sanofi, has worked in both the public and private sectors with a focus on field and clinical research and new vaccine policy and programs for more than 30 years.
Most recently, Dr. Nelson has focused on the launch of a long-acting respiratory syncytial virus (RSV) monoclonal antibody (nirsevimab) for all infants.
Before joining Sanofi Pasteur in 2014, Dr. Nelson was the founding Director of the Coalition against Typhoid (CaT) Secretariat at the Sabin Vaccine Institute, and before this worked at Merck. From 1997 to 2006, Dr. Nelson was at the World Health Organization (WHO) in Geneva, Switzerland.
Throughout his career he has focused on support of new vaccine policy and programs (HepB, Hib (pentavalent), meningococcal, rotavirus, HPV, typhoid/paratyphoid, dengue, RSV, influenza) in Africa, the Middle East, Asia, Latin America and the Caribbean, Europe, and North America. This included leading a successful Public-Private Partnership (PPP) to deliver a meningococcal vaccine in response to the Meningitis Belt W135 outbreak. He has also served as the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) representative to international organizations, including the WHO, UNICEF, the GAVI Alliance, and the Bill & Melinda Gates Foundation.
